Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hassan, A. B.
Right arrow Articles by Macaulay, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hassan, A. B.
Right arrow Articles by Macaulay, V. M.
Related Collections
Right arrow 2002 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:349-356, 2002
© 2002 European Society for Medical Oncology

The insulin-like growth factor system as a therapeutic target in colorectal cancer

A. B. Hassan1,+ and V. M. Macaulay2

1Cell and Development Group, Department of Zoology, University of Oxford, Oxford; 2Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK

Received 15 June 2001; revised 5 October 2001; accepted 23 October 2001.

The purpose of this review is to examine recent evidence that investigates the role of the insulin-like growth factor (IGF) system in colorectal cancer. We concentrate on the evidence that makes the case for the investigation of strategies that might be used to disrupt the IGF system in prevention and treatment. Even though the weight of evidence suggests that components of the IGF system may be appropriate targets, there are a lack of studies that make a systematic characterisation of all the system components in human colorectal cancer. It is anticipated that this information, and the new therapeutic molecules which follow, will impact on the prevention and treatment of patients with this disease.

Key words: colorectal cancer, growth factors, insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor-I receptor, insulin-like growth factor-II receptor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Q.-s. Ji, M. J. Mulvihill, M. Rosenfeld-Franklin, A. Cooke, L. Feng, G. Mak, M. O'Connor, Y. Yao, C. Pirritt, E. Buck, et al.
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo
Mol. Cancer Ther., August 1, 2007; 6(8): 2158 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Hoh, D. Boocock, T. Marczylo, R. Singh, D. P. Berry, A. R. Dennison, D. Hemingway, A. Miller, K. West, S. Euden, et al.
Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences.
Clin. Cancer Res., May 1, 2006; 12(9): 2944 - 2950.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Harper, J. L. Burns, E. J. Foulstone, M. Pignatelli, S. Zaina, and A. B. Hassan
Soluble IGF2 Receptor Rescues ApcMin/+ Intestinal Adenoma Progression Induced by Igf2 Loss of Imprinting
Cancer Res., February 15, 2006; 66(4): 1940 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Miyamoto, M. Nakamura, K. Shitara, K. Nakamura, Y. Ohki, G. Ishii, M. Goya, K. Kodama, T. Sangai, H. Maeda, et al.
Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers
Clin. Cancer Res., May 1, 2005; 11(9): 3494 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Nakamura, S. Miyamoto, H. Maeda, S.-c. Zhang, T. Sangai, G. Ishii, T. Hasebe, Y. Endoh, N. Saito, M. Asaka, et al.
Low Levels of Insulin-Like Growth Factor Type 1 Receptor Expression at Cancer Cell Membrane Predict Liver Metastasis in Dukes' C Human Colorectal Cancers
Clin. Cancer Res., December 15, 2004; 10(24): 8434 - 8441.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al.
A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo
Cancer Res., December 15, 2003; 63(24): 8912 - 8921.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Choi, Y. Kawazoe, K. Murakami, H. Misawa, and M. Uesugi
Identification of Bioactive Molecules by Adipogenesis Profiling of Organic Compounds
J. Biol. Chem., February 21, 2003; 278(9): 7320 - 7324.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.